Toxicity-Reduced, Myeloablative Allograft Followed by Lenalidomide Maintenance as Salvage Therapy for Refractory/Relapsed Myeloma Patients
Bone Marrow Transplantation - United Kingdom
doi 10.1038/bmt.2012.142
Full Text
Open PDFAbstract
Available in full text
Date
August 6, 2012
Authors
Publisher
Springer Science and Business Media LLC